IPM Take
The sharp signal is that TB testing is being redesigned around where patients actually seek care. Sputum-based and central laboratory pathways can miss people who cannot produce sputum, cannot travel, or cannot wait. WHO’s update matters because it pushes diagnosis closer to primary care and communities. The access test is now whether countries can fund, train and monitor decentralised testing without losing quality.
Executive Summary
On 9 March 2026, WHO issued its first recommendations on near point-of-care molecular tests for tuberculosis diagnosis, tongue swab specimens and sputum pooling. WHO says the new guidance aims to make TB testing faster and more accessible, especially where diagnostic gaps persist because of sputum collection difficulties, laboratory-based testing models and high costs. The recommendations include near point-of-care nucleic acid amplification tests for use closer to patients, tongue swabs to simplify sample collection and sputum pooling to improve efficiency for TB and rifampicin-resistant TB testing.
Why it matters
- Public authorities: Need to update national diagnostic algorithms, procurement and training so TB testing can move closer to primary care and community settings.
and governed data infrastructure before cardiovascular AI can be trained and deployed responsibly. - Diagnostics / pathology: Must maintain quality assurance, result reporting and linkage to confirmatory testing while decentralising molecular diagnosis.
- Patients / advocates: Easier sampling and nearer testing could reduce missed diagnosis, especially for people who cannot produce sputum or face travel barriers.
Before this update, many TB diagnostic pathways still depended heavily on sputum samples and centralised laboratory testing. That model can delay or miss diagnosis, especially in decentralised, low-resource or high-burden settings.
What has changed is WHO’s explicit support for tools that can work nearer to patients. Near point-of-care molecular tests can be used at peripheral laboratories, primary healthcare centres and community settings. Tongue swabs offer an easier sample option for people who cannot produce sputum. Sputum pooling can help programmes make more efficient use of limited testing resources while supporting detection of TB and rifampicin resistance.
The affected population includes people with suspected TB, particularly those who struggle to produce sputum or face barriers reaching laboratory services. The implementation issue is practical: decentralised diagnostics require staff training, quality assurance, supply chains, connectivity, result reporting and fast linkage to treatment.
For IPM, this is precision public health in practical form: faster diagnosis, closer to the patient, linked to early treatment and resistance detection. A better test only changes outcomes if the pathway can act on the result.
